Nestlé takes stake in Aimmune | Chemical & Engineering News
Volume 94 Issue 45 | p. 15 | Concentrates
Issue Date: November 14, 2016

Nestlé takes stake in Aimmune

Department: Business
Keywords: biotechnology, food allergies, Nestle

Nestlé Health Science is making a $145 million investment in Aimmune Therapeutics, a biotech firm developing treatments for food allergies. Aimmune is working on “characterized oral desensitization technology,” or CODIT, a way of desensitizing a patient to a food allergen by gradually increasing exposure over a period of months. The biotech’s lead product, AR101, is in Phase III studies for people with peanut allergies. The companies also signed a two-year research pact to develop other oral immunotherapies.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment